A Phase 3 interventional study of Symbicort and Symbicort in Asthma, sponsored by AstraZeneca. Completed at 41 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2014-03-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 44th largest by enrollment of the 108 interventional ones that give a count, is one of 2 that started in 2011, is one of 51 in phase 3, and was the 72nd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 118th largest by enrollment of the 248 interventional ones that give a count, is one of 15 that started in 2011, is one of 121 in phase 3, and was the 158th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Symbicort BA MDI 2x160/4.5 μg twice daily
Drug: Symbicort
Symbicort AC pDMI 2x160/4.5 μg twice daily
Drug: Symbicort
Budesonide AC pMDI 2x160 μg twice daily
Drug: Budesonide
Breath actuated metered dose inhaler
Actuation counter pressured metered dose inhaler
Actuation counter pressured metered dose inhaler
Forced Expiratory Volume in 1 Second (FEV1) - Post Dose
Descriptive statistics for post-dose FEV1 (L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.
Time frame: 60 minutes post-dose in clinic visits at baseline, and week 0, 3, 7, 12 and Trt Avg
Forced Expiratory Volume in 1 Second (FEV1) - Pre Dose
Descriptive statistics for predose FEV1(L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.
Time frame: Pre AM dose in clinic visits at baseline, and week 3, 7, 12 and Trt Avg
Peak Expiratory Flow
Time frame: Recorded morning upon rising and evening before sleep for 14 weeks
Asthma Symptoms Score (Total)
The total score is calculated as sum of the morning and evening scores of each day and the treatment period mean score is defined as the mean of all total score recorded during the 12-week treatment period. Trt Avg=Mean total score of double-blind period values.(day/night score ranges from 0 to 3; 0=no asthma symptoms; 3= unable to do normal activities (or to sleep) due to asthma). Higher score represents worse outcome.
Time frame: Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks
Night-time Awakenings Due to Asthma Symptoms(% Awakening-free Nights)
The percentage of days with no awakenings due to asthma. Baseline= Mean % awakening-free nights during run-in period ; Trt Avg=Mean % awakening-free nights during double-blind period.
Time frame: Recorded 6:00 - 11:00 AM for 14 weeks
Use of Rescue Medication Day and Night (Total Daily Rescue Medication Use)
Total daily rescue medication use is calculated as the sum of morning and evening use each day and averaged over the 12 weeks treatment periods to calculate the treatment period mean. Baseline= Mean rescue medication used during run-in period ; Trt Avg=Mean rescue medication used during double-blind period.
Time frame: Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks
| Milestone | Symbicort BA MDI | Symbicort pMDI | Budesonide |
|---|---|---|---|
| Started | 71 | 71 | 72 |
| Completed | 63 | 67 | 65 |
| Not completed | 8 | 4 | 7 |
| Withdrew: Eligibility criteria + other | 2 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 0 | 2 |
| Withdrew: Adverse event | 2 | 3 | 3 |
Descriptive statistics for post-dose FEV1 (L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.
| Liter | Symbicort BA MDI | Symbicort pMDI | Budesonide |
|---|---|---|---|
| Baseline | 2.09 ± 31.46 | 1.97 ± 27.16 | 2.12 ± 26.34 |
| Week 0 | 2.49 ± 32.14 | 2.35 ± 25.97 | 2.28 ± 27.18 |
| Week 3 | 2.52 ± 31.98 | 2.34 ± 26.31 | 2.30 ± 30.22 |
| Week 7 | 2.59 ± 32.17 | 2.35 ± 27.22 | 2.33 ± 29.29 |
| Week 12 | 2.52 ± 30.71 | 2.39 ± 27.31 | 2.30 ± 28.27 |
| Treatment Average | 2.53 ± 30.57 | 2.37 ± 26.33 | 2.30 ± 28.36 |
Descriptive statistics for predose FEV1(L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.
| Liters | Symbicort BA MDI | Symbicort pMDI | Budesonide |
|---|---|---|---|
| Baseline | 2.09 ± 31.46 | 1.97 ± 27.16 | 2.12 ± 26.34 |
| Week 3 | 2.32 ± 32.79 | 2.12 ± 28.29 | 2.22 ± 31.21 |
| Week 7 | 2.40 ± 32.86 | 2.11 ± 29.96 | 2.25 ± 29.01 |
| Week 12 | 2.34 ± 30.84 | 2.17 ± 31.29 | 2.23 ± 30.15 |
| Average of treatment period | 2.34 ± 30.15 | 2.15 ± 29.15 | 2.23 ± 29.36 |
| L/Min | Symbicort BA MDI | Symbicort pMDI | Budesonide |
|---|---|---|---|
| Morning Peak expiratory flow (Baseline) | 357.95 ± 100.59 | 335.70 ± 102.99 | 360.46 ± 103.09 |
| Evening Peak expiratory flow (Baseline) | 364.61 ± 103.62 | 347.86 ± 110.80 | 367.64 ± 102.73 |
| Evening Peak expiratory flow (Treatment Average) | 379.96 ± 104.72 | 362.99 ± 112.63 | 348.94 ± 97.94 |
| Morning Peak expiratory flow (Treatment Average) | 376.28 ± 106.76 | 353.69 ± 108.72 | 343.59 ± 98.12 |
The total score is calculated as sum of the morning and evening scores of each day and the treatment period mean score is defined as the mean of all total score recorded during the 12-week treatment period. Trt Avg=Mean total score of double-blind period values.(day/night score ranges from 0 to 3; 0=no asthma symptoms; 3= unable to do normal activities (or to sleep) due to asthma). Higher score represents worse outcome.
| Asthma score on a scale of 0 to 3 | Symbicort BA MDI | Symbicort pMDI | Budesonide |
|---|---|---|---|
| Baseline | 2.04 ± 0.98 | 1.92 ± 0.72 | 2.12 ± 0.88 |
| Treatment Average (Trt Avg) | 1.68 ± 1.10 | 1.45 ± 0.91 | 2.02 ± 0.96 |
The percentage of days with no awakenings due to asthma. Baseline= Mean % awakening-free nights during run-in period ; Trt Avg=Mean % awakening-free nights during double-blind period.
| Percentage of days with no awakenings | Symbicort BA MDI | Symbicort pMDI | Budesonide |
|---|---|---|---|
| Baseline | 78.54 ± 28.97 | 78.76 ± 29.76 | 81.59 ± 25.32 |
| Treatment Average (Trt Avg) | 83.73 ± 30.90 | 89.93 ± 21.40 | 84.62 ± 26.31 |
Total daily rescue medication use is calculated as the sum of morning and evening use each day and averaged over the 12 weeks treatment periods to calculate the treatment period mean. Baseline= Mean rescue medication used during run-in period ; Trt Avg=Mean rescue medication used during double-blind period.
| Inhalations/24 hrs | Symbicort BA MDI | Symbicort pMDI | Budesonide |
|---|---|---|---|
| Baseline | 2.55 ± 2.48 | 2.19 ± 1.75 | 2.65 ± 2.36 |
| Treatment Average (Trt Avg) | 1.81 ± 2.67 | 1.26 ± 1.60 | 2.34 ± 2.38 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Budesonide | — | 0/71 (0%) | 3/71 (4.2%) |
| Symbicort BA MDI | — | 0/71 (0%) | 2/71 (2.8%) |
| Symbicort pMDI | — | 1/71 (1.4%) | 7/71 (9.9%) |
| Event | Budesonide | Symbicort BA MDI | Symbicort pMDI |
|---|---|---|---|
| APPENDICITISInfections and infestations | 0/71 | 0/71 | 1/71 |
| Event | Budesonide | Symbicort BA MDI | Symbicort pMDI |
|---|---|---|---|
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/71 | 2/71 | 7/71 |
All Randomized patients
| Age, Continuous(Years) | Symbicort BA MDI | Symbicort pMDI | Budesonide | Total |
|---|---|---|---|---|
| Mean | 42.83 ± 16.156 | 42.62 ± 16.873 | 42.72 ± 14.424 | 42.72 ± 15.770 |
| Age, Customized(Participants) | Symbicort BA MDI | Symbicort pMDI | Budesonide | Total |
|---|---|---|---|---|
| 12 - <18 years | 6 | 8 | 7 | 21 |
| 18 - <65 years | 60 | 56 | 62 | 178 |
| 65 - <75 years | 4 | 4 | 2 | 10 |
| >= 75 years | 1 | 3 | 1 | 5 |
| Sex: Female, Male(Participants) | Symbicort BA MDI | Symbicort pMDI | Budesonide | Total |
|---|---|---|---|---|
| Female | 37 | 47 | 35 | 119 |
| Male | 34 | 24 | 37 | 95 |
| Race (NIH/OMB)(Participants) | Symbicort BA MDI | Symbicort pMDI | Budesonide | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 4 | 1 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 9 | 7 | 11 | 27 |
| White | 57 | 63 | 57 | 177 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 2 | 3 |
| Years since asthma diagnosis(Years) | Symbicort BA MDI | Symbicort pMDI | Budesonide | Total |
|---|---|---|---|---|
| Mean | 24.26 ± 14.891 | 24.12 ± 15.128 | 24.38 ± 15.183 | 24.25 ± 14.998 |
| % Predicted FEV1 (Visit 2)(%) | Symbicort BA MDI | Symbicort pMDI | Budesonide | Total |
|---|---|---|---|---|
| Mean | 67.27 ± 10.048 | 65.02 ± 11.135 | 68.49 ± 9.924 | 66.93 ± 10.434 |
| % Reversibility in FEV1 (Visit 2)(%) | Symbicort BA MDI | Symbicort pMDI | Budesonide | Total |
|---|---|---|---|---|
| Mean | 23.93 ± 15.728 | 28.04 ± 14.712 | 23.64 ± 12.692 | 25.20 ± 14.491 |
| % Reversibility in FEV1 (Visit 3)(%) | Symbicort BA MDI | Symbicort pMDI | Budesonide | Total |
|---|---|---|---|---|
| Mean | 26.43 ± 16.662 | 28.22 ± 16.118 | 24.88 ± 14.235 | 26.51 ± 15.692 |
1 further baseline measures are reported on the registry.
The record gives a start of Nov 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide